Ventyx Biosciences (NASDAQ:VTYX) Shares Down 3.4% – Time to Sell?

Ventyx Biosciences, Inc. (NASDAQ:VTYX)’s stock price was down 3.4% during mid-day trading on Tuesday . The stock traded as low as $8.73 and last traded at $8.77. Approximately 183,117 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 2,065,083 shares. The stock had previously closed at $9.08.

Wall Street Analyst Weigh In

VTYX has been the subject of a number of recent analyst reports. Wells Fargo & Company raised their price objective on Ventyx Biosciences from $11.00 to $14.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Canaccord Genuity Group increased their price objective on shares of Ventyx Biosciences from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, November 7th. HC Wainwright raised shares of Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 target price for the company in a report on Wednesday, November 5th. Oppenheimer increased their price target on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a report on Monday, October 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

Ventyx Biosciences Price Performance

The stock has a 50-day moving average of $8.54 and a 200-day moving average of $4.80. The firm has a market cap of $619.76 million, a price-to-earnings ratio of -5.79 and a beta of 1.22.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.13. On average, equities analysts expect that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

Insider Activity

In related news, insider John Nuss sold 12,675 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $97,851.00. Following the completion of the transaction, the insider directly owned 489,481 shares of the company’s stock, valued at $3,778,793.32. This trade represents a 2.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Raju Mohan sold 47,345 shares of Ventyx Biosciences stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the transaction, the chief executive officer directly owned 2,372,863 shares in the company, valued at $18,318,502.36. The trade was a 1.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 18.18% of the company’s stock.

Institutional Trading of Ventyx Biosciences

Several institutional investors have recently added to or reduced their stakes in VTYX. Jacobs Levy Equity Management Inc. bought a new stake in shares of Ventyx Biosciences in the 3rd quarter valued at $61,000. Woodline Partners LP bought a new position in shares of Ventyx Biosciences in the 3rd quarter worth about $143,000. XTX Topco Ltd lifted its stake in shares of Ventyx Biosciences by 25.2% in the 3rd quarter. XTX Topco Ltd now owns 202,382 shares of the company’s stock valued at $629,000 after purchasing an additional 40,771 shares during the period. Vestal Point Capital LP boosted its position in shares of Ventyx Biosciences by 2.5% during the 3rd quarter. Vestal Point Capital LP now owns 2,050,000 shares of the company’s stock valued at $6,376,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new stake in Ventyx Biosciences during the third quarter worth approximately $456,000. 97.88% of the stock is currently owned by institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.